Vault-13

ARCELLX INC ACLX

COMMON STOCK · Common Stock · CUSIP 03940C100

2 institutional holders -238 vs Q1 2026
30,01330.0k shares reported held*
$3.4mreported value*
0 new 1 added 0 reduced 229 sold out net sold ≈ $6.4bn (-55.7m shares)

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $114.33.

Trends to Q2 2026

Institutional holders

Managers reporting a position, each quarter

0100200300Q3 22: 74Q4 22: 127Q1 23: 119Q2 23: 140Q3 23: 138Q4 23: 158Q1 24: 184Q2 24: 168Q3 24: 187Q4 24: 213Q1 25: 200Q2 25: 205Q3 25: 210Q4 25: 219Q1 26: 240Q2 26: 22Q3 22Q3 23Q3 24Q3 25Q2 26
Numbers
QuarterHolders
Q3 202274
Q4 2022127
Q1 2023119
Q2 2023140
Q3 2023138
Q4 2023158
Q1 2024184
Q2 2024168
Q3 2024187
Q4 2024213
Q1 2025200
Q2 2025205
Q3 2025210
Q4 2025219
Q1 2026240
Q2 20262

Buyers vs sellers

Managers adding to or starting a position, vs cutting or selling out

Bought or addedCut or sold out
4000400Q3 24: 102 bought or addedQ3 24: 79 cut or sold outQ4 24: 112 bought or addedQ4 24: 79 cut or sold outQ4 24Q1 25: 97 bought or addedQ1 25: 107 cut or sold outQ2 25: 90 bought or addedQ2 25: 106 cut or sold outQ2 25Q3 25: 87 bought or addedQ3 25: 101 cut or sold outQ4 25: 108 bought or addedQ4 25: 102 cut or sold outQ4 25Q1 26: 146 bought or addedQ1 26: 127 cut or sold outQ2 26: 1 bought or addedQ2 26: 229 cut or sold outQ2 26
Numbers
QuarterBought or addedCut or sold out
Q3 202410279
Q4 202411279
Q1 202597107
Q2 202590106
Q3 202587101
Q4 2025108102
Q1 2026146127
Q2 20261229

Calls vs puts

Options held, notional value, last 4 quarters. P/C = puts ÷ calls

CallsPuts
$0$50m$100m$150mQ3 25 calls: $7.5mQ3 25 puts: $9.6mQ3 25P/C 1.29Q4 25 calls: $21.8mQ4 25 puts: $16.4mQ4 25P/C 0.75Q1 26 calls: $128.0mQ1 26 puts: $45.1mQ1 26P/C 0.35Q2 26 calls: $0Q2 26 puts: $0Q2 26P/C —
Numbers
QuarterCallsPutsP/C
Q3 2025$7.5m$9.6m1.29
Q4 2025$21.8m$16.4m0.75
Q1 2026$128.0m$45.1m0.35
Q2 2026$0$0—

Biggest buyers

IFP Advisors, Inc Added +1+1

Biggest sellers

GILEAD SCIENCES, INC. Sold out -6,720,803-6.7m
Paradigm Biocapital Advisors LP Sold out -5,774,016-5.8m
BlackRock, Inc. Sold out -3,945,238-3.9m
NEA Management Company, LLC Sold out -3,045,262-3.0m
Pentwater Capital Management LP Sold out -2,870,000-2.9m
VANGUARD CAPITAL MANAGEMENT LLC Sold out -2,425,218-2.4m
VANGUARD PORTFOLIO MANAGEMENT LLC Sold out -2,424,818-2.4m
SR One Capital Management, LP Sold out -2,346,630-2.3m
FIL Ltd Sold out -2,339,192-2.3m
HBK INVESTMENTS L P Sold out -2,278,517-2.3m

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
GILEAD SCIENCES, INC. 13D · may seek influence +88.5 pts · filed 2026-04-28
Stated purposeItem 4 of the Original Schedule 13D is amended to include the following at the end thereof: "As previously disclosed, Gilead, Purchaser and Arcellx entered into the Merger Agreement pursuant to which Purchaser commenced the Offer on March 6, 2026. The Offer expired at 5:00 p.m., Eastern Time, on April 27, 2026. Computershare Trust Company N.A., the depositary and paying agent for the Offer, advised Gilead that, as of the expiration of the Offer, 38,795,604 Shares had been validly tendered and not validly withdrawn pursuant to the Offer, representing, together with Shares already owned by Gilead, approximately 77.2% of the Shares outstanding as of the expiration of the Offer. Following consummation of the Offer, on April 28, 2026, Gilead completed its acquisition of Arcellx through the m… Full filing
 100.0% +88.5 pts 100 2026-04-28
BlackRock, Inc. 13G · institution filed 2025-04-17 6.4% 3.5m 2025-04-17

Fell to 5% or below in the last year: Paradigm Biocapital Advisors LP (0.0%, 2026-08-14), Vestal Point Capital, LP (0.0%, 2026-05-15), New Enterprise Associates 15, L.P. (0.0%, 2026-04-30), Elghandour Rami (0.0%, 2026-04-28), VANGUARD GROUP INC (0.0%, 2026-03-26), T. Rowe Price Investment Management, Inc. (4.5%, 2026-03-06), FMR LLC (0.5%, 2026-03-06), RA CAPITAL MANAGEMENT, L.P. (2.2%, 2026-02-17)

Holders, Q2 2026

#ManagerLocationShares Value% of their portfolioChangeShares change
1 DekaBank Deutsche Girozentrale 0.01% of their portfolio FRANKFURT, 2M 30,00030.0k $3.4m $3.4m 0.01% Unchanged
2 IFP Advisors, Inc 0.00% of their portfolio TAMPA, FL 1313 $1.5k $1.5k 0.00% Added +1 +1